George C. Clark Biohaven Pharmaceutical Holding CO Ltd. (BHVN) insider trading activity

George C. Clark is VP, Chief Accounting Officer of Biohaven Pharmaceutical Holding Co Ltd.. Currently has a direct ownership of 0 shares of BHVN, which is worth approximately $0. The most recent transaction as insider was on Oct 03, 2022, when has been sold 4,292 shares (Common Shares) at a price of $148.5 per share, resulting in proceeds of $637,362. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

George C. Clark Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 03 2022	SELL Sale (or disposition) back to the issuer	$637,362 $148.5 p/Share	4,292 Reduced 100.0%	0 Common Shares
May 10 2022	SELL Open market or private sale	$594,300 $141.5 p/Share	4,200 Reduced 50.82%	4,065 Common Shares
May 10 2022	BUY Exercise of conversion of derivative security	$120,960 $53.76 p/Share	2,250 Added 21.4%	8,265 Common Shares
Jan 19 2022	SELL Open market or private sale	$1,097,719 $117.09 p/Share	9,375 Reduced 60.92%	6,015 Common Shares
Jan 19 2022	BUY Exercise of conversion of derivative security	$244,320 $43.09 p/Share	5,670 Added 26.92%	15,390 Common Shares
Jan 10 2022	SELL Payment of exercise price or tax liability	$59,796 $128.87 p/Share	464 Reduced 4.56%	9,720 Common Shares
Jan 10 2022	BUY Exercise of conversion of derivative security	-	1,000 Added 8.94%	10,184 Common Shares
Jan 07 2022	SELL Payment of exercise price or tax liability	$67,270 $128.87 p/Share	522 Reduced 5.38%	9,184 Common Shares
Jan 07 2022	BUY Exercise of conversion of derivative security	-	1,000 Added 9.34%	9,706 Common Shares
Jan 06 2022	SELL Payment of exercise price or tax liability	$50,659 $123.86 p/Share	409 Reduced 4.49%	8,706 Common Shares
Jan 06 2022	BUY Exercise of conversion of derivative security	-	875 Added 8.76%	9,115 Common Shares
Dec 20 2021	SELL Open market or private sale	$237,154 $123.84 p/Share	1,915 Reduced 18.86%	8,240 Common Shares
Nov 26 2021	SELL Payment of exercise price or tax liability	$267,845 $115.55 p/Share	2,318 Reduced 18.58%	10,155 Common Shares
Nov 26 2021	BUY Exercise of conversion of derivative security	-	5,000 Added 28.62%	12,473 Common Shares
Nov 23 2021	BUY Exercise of conversion of derivative security	$62,084 $32.42 p/Share	1,915 Added 20.4%	7,473 Common Shares

Also insider at

BHVN

Biohaven Ltd.

VP, Chief Accounting Officer

GCC

George C. Clark

VP, Chief Accounting Officer

New Haven, CT

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BHVN shares.

Notify only if

Value

Insider Trading

Get notified when an Biohaven Pharmaceutical Holding CO Ltd. insider buys or sells BHVN shares.

Notify only if

Operation

Value

Type

News

Receive news related to Biohaven Pharmaceutical Holding Co Ltd.

Track Activities on BHVN

Account